Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Jacobio Pharmaceuticals Co. Ltd. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct art units, indicating technical variety within the active docket. The prosecution involves 5 distinct examiners, meaning each pending action is currently assigned to a different individual at the USPTO.
Kevin E. Weddington is identified as the busiest examiner for this portfolio, although he is responsible for 1 pending office action. Because there are 5 distinct examiners, the workload is distributed with no single examiner handling more than 1 case. This lack of concentration means that prosecution outcomes are dependent on the individual tendencies of different examiners.
The 4 distinct art units involved indicate that the 5 pending office actions are spread across multiple specialized technical groups. With 5 distinct examiners across 4 art units, the company faces a range of perspectives. Practitioners should prepare for diverse examiner feedback across the active matters in this Biotechnology & Pharmaceuticals portfolio, as each case is being handled by a different examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283834 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | 60d |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | MOU, LIYUAN | — |
| 18284897 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18818701 | TRICYCLIC COMPOUNDS | WEDDINGTON, KEVIN E | — | Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18284897 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | MCMILLIAN, KARA RENITA | 1623 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18283834 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Non-Final OA | 60d | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial